Literature DB >> 9478007

Antimetabolite-induced apoptosis in Tenon's capsule fibroblasts.

J G Crowston1, A N Akbar, P H Constable, N L Occleston, J T Daniels, P T Khaw.   

Abstract

PURPOSE: To determine whether treatment with mitomycin-c and 5-fluorouracil induces apoptotic death in cultured subconjunctival fibroblasts.
METHODS: Cultured human subconjunctival Tenon's capsule fibroblasts were exposed to 5-minute applications of mitomycin-C (up to 1 mg/ml) or 5-fluorouracil (up to 50 mg/ml) or phosphate-buffered saline solution (PBS). Fibroblast apoptosis was determined by cell morphology, apoptosis-specific protein expression, and DNA fragmentation by TdT-mediated dUTP nick-end labeling (TUNEL). In addition, apoptosis was quantified by direct cell counts based on morphology or lactate dehydrogenase release.
RESULTS: Morphologic changes characteristic of apoptosis included nuclear and cytoplasmic condensation and occasional nuclear fragmentation while the plasma membrane remained intact. Apoptosis-specific protein expression and DNA fragmentation was observed in fibroblasts 48 hours after mitomycin-C treatment but not in control PBS-treated fibroblasts. The amount of apoptosis induced was dose dependent and partially inhibited by the addition of fetal calf serum to growth medium immediately after treatment.
CONCLUSIONS: Mitomycin-C and high-dose 5-fluorouracil induce apoptosis in cultured Tenon's fibroblasts. Mitomycin-C-induced apoptosis is inhibited by fetal calf serum, indicating that exogenous factors influence the susceptibility of a fibroblast population to apoptosis. The induction and regulation of fibroblast apoptosis provides a novel target for the potential regulation of scarring.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9478007

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  40 in total

1.  Quantifying corneal endothelial cell death.

Authors:  J G Crowston; P R Healey; A Maloof; B Allan
Journal:  Br J Ophthalmol       Date:  2002-09       Impact factor: 4.638

Review 2.  Prevention and treatment of excessive dermal scarring.

Authors:  Ingrid E Roseborough; Mark A Grevious; Raphael C Lee
Journal:  J Natl Med Assoc       Date:  2004-01       Impact factor: 1.798

3.  T lymphocyte mediated lysis of mitomycin C treated Tenon's capsule fibroblasts.

Authors:  J G Crowston; L H Chang; J T Daniels; P T Khaw; A N Akbar
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

4.  Management of keloid and hypertrophic scars.

Authors:  A S Edriss; J Mesták
Journal:  Ann Burns Fire Disasters       Date:  2005-12-31

5.  In vivo magnetic resonance imaging and optical imaging comparison of viable and nonviable mesenchymal stem cells with a bifunctional label.

Authors:  Elizabeth Jane Sutton; Tobias D Henning; Sophie Boddington; Stavros Demos; Christian Krug; Reinhardt Meier; John Kornak; Shoujun Zhao; Rick Baehner; Sheida Sharifi; Heike Daldrup-Link
Journal:  Mol Imaging       Date:  2010-10       Impact factor: 4.488

6.  Trypan blue identifies antimetabolite treatment area in trabeculectomy.

Authors:  P R Healey; J G Crowston
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

7.  Comparison of 90-s versus 5-min intraoperative 5-fluorouracil in trabeculectomy.

Authors:  Andrea Zarkovic; Kent Chow; Justin S Mora
Journal:  Int Ophthalmol       Date:  2009-01-10       Impact factor: 2.031

8.  Anti-scarring effects of butaprost on human subconjunctival Tenon's fibroblasts.

Authors:  Jong Hoon Shin; Je Hyun Seo; Jae Ho Jung; Tae Woo Kim
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

9.  Suppression of transforming growth factor-β effects in rabbit subconjunctival fibroblasts by activin receptor-like kinase 5 inhibitor.

Authors:  Jennifer Sapitro; Jeffrey J Dunmire; Sarah E Scott; Vijay Sutariya; Werner J Geldenhuys; Michael Hewit; Beatrice Y J T Yue; Hiroshi Nakamura
Journal:  Mol Vis       Date:  2010-09-16       Impact factor: 2.367

10.  Human tissue factor pathway inhibitor-2 suppresses the wound-healing activities of human Tenon's capsule fibroblasts in vitro.

Authors:  Yuan Jing; Yu Jian-Xiong
Journal:  Mol Vis       Date:  2009-11-12       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.